Revised SPC: Erleada (apalutamide) 60 mg film coated tablets

Treatment of metastatic hormone-sensitive prostate cancer added as a new licensed indication. Recommendation to monitor for symptoms of IHD and management of CV risk factors added. Hypertension, hot flush, diarrhoea & weight loss have been added as common adverse effects.


electronic Medicines compendium